<p>Rhythm Pharmaceuticals（纳斯达克代码：RYTM - 获取免费报告）在周四发布的研究报告中，Needham
&amp; Company LLC 将其目标价格从 120.00 美元上调至 145.00 美元，Benzinga 报道。该公司目前对该股票给予 “买入” 评级。Needham
&amp; Company LLC 的价格目标意味着该股票当前价格有 21.35% 的潜在上涨空间。</p>
<ul>
<li>7 只将推动减肥药市场的股票</li>
</ul>
<p>其他几位股票研究分析师也对 RYTM 发表了看法。JMP Securities 将 Rhythm Pharmaceuticals 的股票目标价格从 135.00 美元上调至 142.00 美元，并在 9 月 25 日的研究报告中给予该股票 “市场表现优于大盘” 的评级。华尔街 Zen 在 11 月 8 日的研究报告中将 Rhythm Pharmaceuticals 的股票评级从 “持有” 下调至 “卖出”。Weiss Ratings 在 10 月 8 日的报告中重申了对 Rhythm Pharmaceuticals 的 “卖出（d-）” 评级。摩根士丹利在 10 月 16 日的研究报告中将 Rhythm Pharmaceuticals 的目标价格从 122.00 美元上调至 129.00 美元，并给予该股票 “增持” 评级。最后，HC Wainwright 在 9 月 29 日的报告中将 Rhythm Pharmaceuticals 的目标价格从 100.00 美元上调至 110.00 美元，并给予该公司 “买入” 评级。一位研究分析师给予该股票 “强烈买入” 评级，十三位分析师给予 “买入” 评级，一位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价格为 116.50 美元。</p>
<p>获取 <strong>Rhythm Pharmaceuticals</strong> 的提醒：</p>
<p><strong>阅读我们关于 RYTM 的最新研究报告</strong></p>
<h2>Rhythm Pharmaceuticals 股价上涨 14.0%</h2>
<ul>
<li>2 家生物科技公司推出有前景的减肥药</li>
</ul>
<p>周四交易时段，RYTM 股票上涨 14.72 美元，达到 119.49 美元。该公司的股票交易量为 2,410,748 股，而其平均交易量为 666,357 股。该公司的 50 日移动平均线为 104.61 美元，200 日移动平均线为 91.49 美元。该股票的市值为 79.7 亿美元，市盈率为-38.55，贝塔值为 1.96。Rhythm Pharmaceuticals 的 12 个月低点为 45.90 美元，12 个月高点为 122.20 美元。</p>
<p>Rhythm Pharmaceuticals（纳斯达克代码：RYTM - 获取免费报告）最近于 11 月 4 日发布了季度财报。该公司报告每股收益（EPS）为-0.82 美元，低于共识预期的-0.72 美元，差距为 0.10 美元。该公司季度收入为 5130 万美元，而分析师预期为 5071 万美元。Rhythm Pharmaceuticals 的股本回报率为-433.21%，净利润率为-110.32%。平均而言，股票分析师预计 Rhythm Pharmaceuticals 在当前财政年度将发布-4.32 的每股收益。</p>
<h2>Rhythm Pharmaceuticals 的内部交易</h2>
<p>在 Rhythm Pharmaceuticals 的其他消息中，内部人士 Joseph Shulman 于 10 月 30 日星期四出售了 9,748 股该公司的股票。该股票以 115.24 美元的平均价格出售，总价值为 1,123,359.52 美元。交易完成后，内部人士在公司中持有 8,509 股，价值 980,577.16 美元。此交易代表其持股比例减少了 53.39%。该出售在向证券交易委员会提交的文件中披露，文件可通过此超链接获取。在过去的一个季度中，内部人士共出售了价值 3,064,490 美元的 27,000 股公司股票。内部人士持有公司 6.10% 的股份。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者最近调整了对该股票的持有。Smartleaf Asset Management LLC 在第三季度将其在 Rhythm Pharmaceuticals 的股份增加了 97.2%。Smartleaf Asset Management LLC 目前持有 286 股该公司的股票，价值 29,000 美元，此前在上个季度购买了 141 股。BI Asset Management Fondsmaeglerselskab A S 在第一季度购买了 Rhythm Pharmaceuticals 的新股份，价值约 34,000 美元。Farther Finance Advisors LLC 在第三季度将其在 Rhythm Pharmaceuticals 的股份增加了 1,110.3%。Farther Finance Advisors LLC 目前持有 351 股该公司的股票，价值 35,000 美元，此前在此期间购买了 322 股。Optiver Holding B.V.在第三季度将其在 Rhythm Pharmaceuticals 的持股增加了 65.2%。Optiver Holding B.V.目前持有 365 股该公司的股票，价值 37,000 美元，此前在上个季度增加了 144 股。最后，Osaic Holdings Inc.在第二季度将其在 Rhythm Pharmaceuticals 的持股增加了 65.9%。Osaic Holdings Inc.目前持有 979 股该公司的股票，价值 62,000 美元，此前在上个季度增加了 389 股。</p>
<h2>Rhythm Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Rhythm Pharmaceuticals, Inc.是一家商业阶段的生物制药公司，专注于罕见的神经内分泌疾病。该公司的主要产品候选药物是 IMCIVREE（setmelanotide），用于治疗促黑激素前体（POMC）、前蛋白转化酶亚型 1、瘦素受体（LEPR）缺乏症肥胖以及巴尔代 - 比德尔综合症和阿尔斯特综合症。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Rhythm Pharmaceuticals</li>
<li>如何使用 MarketBeat 股息计算器</li>
<li>AST SpaceMobile 为下周的 BlueBird 6 发射做好准备</li>
<li>复利是如何计算的？</li>
<li>人工智能与量子计算的下一个赢家：2026 年值得关注的 3 只小盘股</li>
<li>什么是 SEC 文件？</li>
<li>三只冬季股票，具有良好的增长机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Rhythm Pharmaceuticals 吗？</h2>
<p>在考虑 Rhythm Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Rhythm Pharmaceuticals 并不在名单上。</p>
<p>虽然 Rhythm Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RYTM

<p>Needham & Company LLC 将 Rhythm Pharmaceuticals 的目标股价从 120 美元上调至 145 美元，维持 “买入” 评级，表明潜在上涨幅度为 21.35%。其他分析师的评级各不相同，普遍共识为 “适度买入”，平均目标股价为 116.50 美元。该股票最近上涨了 14%，达到 119.49 美元，市值为 79.7 亿美元</p>

<p>Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) had its target price upped by investment analysts at Needham &amp; Company LLC from $120.00 to $145.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. Needham &amp; Company LLC's price objective would indicate a potential upside of 21.35% from the stock's current price.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals（纳斯达克代码：RYTM - 获取免费报告）在周四发布的研究报告中，Needham
&amp; Company LLC 将其目标价格从 120.00 美元上调至 145.00 美元，Benzinga 报道。该公司目前对该股票给予 “买入” 评级。Needham
&amp; Company LLC 的价格目标意味着该股票当前价格有 21.35% 的潜在上涨空间。</p>
</div><ul>
<li>7 Stocks That Will Drive the Weight Loss Drugs Market</li>
</ul>
<div class="lb-trans"><ul>
<li>7 只将推动减肥药市场的股票</li>
</ul>
</div><p>Several other equities research analysts have also weighed in on RYTM. JMP Securities increased their price objective on shares of Rhythm Pharmaceuticals from $135.00 to $142.00 and gave the stock a &#34;market outperform&#34; rating in a research note on Thursday, September 25th. Wall Street Zen lowered shares of Rhythm Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Rhythm Pharmaceuticals in a report on Wednesday, October 8th. Morgan Stanley boosted their price objective on Rhythm Pharmaceuticals from $122.00 to $129.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, October 16th. Finally, HC Wainwright raised their price target on Rhythm Pharmaceuticals from $100.00 to $110.00 and gave the company a &#34;buy&#34; rating in a report on Monday, September 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $116.50.</p>
<div class="lb-trans"><p>其他几位股票研究分析师也对 RYTM 发表了看法。JMP Securities 将 Rhythm Pharmaceuticals 的股票目标价格从 135.00 美元上调至 142.00 美元，并在 9 月 25 日的研究报告中给予该股票 “市场表现优于大盘” 的评级。华尔街 Zen 在 11 月 8 日的研究报告中将 Rhythm Pharmaceuticals 的股票评级从 “持有” 下调至 “卖出”。Weiss Ratings 在 10 月 8 日的报告中重申了对 Rhythm Pharmaceuticals 的 “卖出（d-）” 评级。摩根士丹利在 10 月 16 日的研究报告中将 Rhythm Pharmaceuticals 的目标价格从 122.00 美元上调至 129.00 美元，并给予该股票 “增持” 评级。最后，HC Wainwright 在 9 月 29 日的报告中将 Rhythm Pharmaceuticals 的目标价格从 100.00 美元上调至 110.00 美元，并给予该公司 “买入” 评级。一位研究分析师给予该股票 “强烈买入” 评级，十三位分析师给予 “买入” 评级，一位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价格为 116.50 美元。</p>
</div><p>Get <strong>Rhythm Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Rhythm Pharmaceuticals</strong> 的提醒：</p>
</div><p><strong>Read Our Latest Research Report on RYTM</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 RYTM 的最新研究报告</strong></p>
</div><h2>Rhythm Pharmaceuticals Trading Up 14.0%</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 股价上涨 14.0%</h2>
</div><ul>
<li>2 biotechs with promising weight-loss drugs coming</li>
</ul>
<div class="lb-trans"><ul>
<li>2 家生物科技公司推出有前景的减肥药</li>
</ul>
</div><p>Shares of RYTM stock traded up $14.72 during trading hours on Thursday, hitting $119.49. The company's stock had a trading volume of 2,410,748 shares, compared to its average volume of 666,357. The business has a fifty day moving average of $104.61 and a 200-day moving average of $91.49. The stock has a market cap of $7.97 billion, a price-to-earnings ratio of -38.55 and a beta of 1.96. Rhythm Pharmaceuticals has a twelve month low of $45.90 and a twelve month high of $122.20.</p>
<div class="lb-trans"><p>周四交易时段，RYTM 股票上涨 14.72 美元，达到 119.49 美元。该公司的股票交易量为 2,410,748 股，而其平均交易量为 666,357 股。该公司的 50 日移动平均线为 104.61 美元，200 日移动平均线为 91.49 美元。该股票的市值为 79.7 亿美元，市盈率为-38.55，贝塔值为 1.96。Rhythm Pharmaceuticals 的 12 个月低点为 45.90 美元，12 个月高点为 122.20 美元。</p>
</div><p>Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.10). The firm had revenue of $51.30 million for the quarter, compared to analyst estimates of $50.71 million. Rhythm Pharmaceuticals had a negative return on equity of 433.21% and a negative net margin of 110.32%. On average, equities analysts expect that Rhythm Pharmaceuticals will post -4.32 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals（纳斯达克代码：RYTM - 获取免费报告）最近于 11 月 4 日发布了季度财报。该公司报告每股收益（EPS）为-0.82 美元，低于共识预期的-0.72 美元，差距为 0.10 美元。该公司季度收入为 5130 万美元，而分析师预期为 5071 万美元。Rhythm Pharmaceuticals 的股本回报率为-433.21%，净利润率为-110.32%。平均而言，股票分析师预计 Rhythm Pharmaceuticals 在当前财政年度将发布-4.32 的每股收益。</p>
</div><h2>Insider Transactions at Rhythm Pharmaceuticals</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 的内部交易</h2>
</div><p>In other Rhythm Pharmaceuticals news, insider Joseph Shulman sold 9,748 shares of the firm's stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $115.24, for a total value of $1,123,359.52. Following the completion of the transaction, the insider owned 8,509 shares in the company, valued at $980,577.16. This trade represents a 53.39% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 27,000 shares of company stock worth $3,064,490. Insiders own 6.10% of the company's stock.</p>
<div class="lb-trans"><p>在 Rhythm Pharmaceuticals 的其他消息中，内部人士 Joseph Shulman 于 10 月 30 日星期四出售了 9,748 股该公司的股票。该股票以 115.24 美元的平均价格出售，总价值为 1,123,359.52 美元。交易完成后，内部人士在公司中持有 8,509 股，价值 980,577.16 美元。此交易代表其持股比例减少了 53.39%。该出售在向证券交易委员会提交的文件中披露，文件可通过此超链接获取。在过去的一个季度中，内部人士共出售了价值 3,064,490 美元的 27,000 股公司股票。内部人士持有公司 6.10% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors have recently modified their holdings of the stock. Smartleaf Asset Management LLC grew its stake in shares of Rhythm Pharmaceuticals by 97.2% in the third quarter. Smartleaf Asset Management LLC now owns 286 shares of the company's stock worth $29,000 after purchasing an additional 141 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Rhythm Pharmaceuticals in the 1st quarter worth approximately $34,000. Farther Finance Advisors LLC increased its stake in shares of Rhythm Pharmaceuticals by 1,110.3% during the third quarter. Farther Finance Advisors LLC now owns 351 shares of the company's stock valued at $35,000 after buying an additional 322 shares during the period. Optiver Holding B.V. raised its holdings in shares of Rhythm Pharmaceuticals by 65.2% during the third quarter. Optiver Holding B.V. now owns 365 shares of the company's stock valued at $37,000 after acquiring an additional 144 shares in the last quarter. Finally, Osaic Holdings Inc. raised its holdings in shares of Rhythm Pharmaceuticals by 65.9% during the second quarter. Osaic Holdings Inc. now owns 979 shares of the company's stock valued at $62,000 after acquiring an additional 389 shares in the last quarter.</p>
<div class="lb-trans"><p>几家机构投资者最近调整了对该股票的持有。Smartleaf Asset Management LLC 在第三季度将其在 Rhythm Pharmaceuticals 的股份增加了 97.2%。Smartleaf Asset Management LLC 目前持有 286 股该公司的股票，价值 29,000 美元，此前在上个季度购买了 141 股。BI Asset Management Fondsmaeglerselskab A S 在第一季度购买了 Rhythm Pharmaceuticals 的新股份，价值约 34,000 美元。Farther Finance Advisors LLC 在第三季度将其在 Rhythm Pharmaceuticals 的股份增加了 1,110.3%。Farther Finance Advisors LLC 目前持有 351 股该公司的股票，价值 35,000 美元，此前在此期间购买了 322 股。Optiver Holding B.V.在第三季度将其在 Rhythm Pharmaceuticals 的持股增加了 65.2%。Optiver Holding B.V.目前持有 365 股该公司的股票，价值 37,000 美元，此前在上个季度增加了 144 股。最后，Osaic Holdings Inc.在第二季度将其在 Rhythm Pharmaceuticals 的持股增加了 65.9%。Osaic Holdings Inc.目前持有 979 股该公司的股票，价值 62,000 美元，此前在上个季度增加了 389 股。</p>
</div><h2>Rhythm Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals, Inc.是一家商业阶段的生物制药公司，专注于罕见的神经内分泌疾病。该公司的主要产品候选药物是 IMCIVREE（setmelanotide），用于治疗促黑激素前体（POMC）、前蛋白转化酶亚型 1、瘦素受体（LEPR）缺乏症肥胖以及巴尔代 - 比德尔综合症和阿尔斯特综合症。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Rhythm Pharmaceuticals</li>
<li>How to Use the MarketBeat Dividend Calculator</li>
<li>AST SpaceMobile Gears Up for Its BlueBird 6 Launch Next Week</li>
<li>How is Compound Interest Calculated?</li>
<li>AI &amp; Quantum's Next Big Winners: 3 Small-Cap Stocks to Watch in 2026</li>
<li>What is a SEC Filing?</li>
<li>Top 3 Winter Stocks With Solid Growth Opportunities</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Rhythm Pharmaceuticals</li>
<li>如何使用 MarketBeat 股息计算器</li>
<li>AST SpaceMobile 为下周的 BlueBird 6 发射做好准备</li>
<li>复利是如何计算的？</li>
<li>人工智能与量子计算的下一个赢家：2026 年值得关注的 3 只小盘股</li>
<li>什么是 SEC 文件？</li>
<li>三只冬季股票，具有良好的增长机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=RYTM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Rhythm Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Rhythm Pharmaceuticals 吗？</h2>
</div><p>Before you consider Rhythm Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Rhythm Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Rhythm Pharmaceuticals 并不在名单上。</p>
</div><p>While Rhythm Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Rhythm Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Needham & Company LLC 的分析师表示，预计 Rhythm Pharmaceuticals（NASDAQ:RYTM）的股价将会上涨